General Announcement::ANDA approval for Aprepitant Capsules USP, 40 mg, 80 mg, and 125 mg

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
16-Oct-2017 13:15:20
Status
New
Announcement Sub Title
ANDA approval for Aprepitant Capsules USP, 40 mg, 80 mg, and 125 mg
Announcement Reference
SG171016OTHRDUL6
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
16/10/2017 10:00:00
Description (Please provide a detailed description of the event in the box below)
Sub: Glenmark Pharmaceuticals receives ANDA approval for Aprepitant Capsules USP, 40 mg, 80 mg, and 125 mg.

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.


Attachments

PR1610.pdf
Total size =824K